	Application No.	Applicant(s)
Notice of Allowability		
	09/884,877 Examiner	TE RIELE ET AL. Art Unit
	Joseph T. Woitach	1632
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>5/8/2006</u> .		
2. The allowed claim(s) is/are <u>33-36,38 and 40-48</u> .		
 3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received. 		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	. =	
1. Notice of References Cited (PTO-892)		atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary Paper No./Mail Dat	(PTO-413), e .
3. A Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date	Paper No./Mail Dat 8), 7. ☐ Examiner's Amendn	nent/Comment
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🛛 Examiner's Stateme	nt of Reasons for Allowance
or biological material	9.	

Application/Control Number: 09/884,877

Art Unit: 1632

DETAILED ACTION

This application filed June 20, 2001 is a continuation in part of 09/147,712, filed February 23, 1999, now abandoned, which is a national stage filing of PCT/EP95/02980, filed July 26, 1995.

Applicants amendment filed May 6, 2006, has been received and entered. The specification has been amended. Claims 1-32, 37, 39, 49 have been canceled. Claims 33, 34 and 48 have been amended. Claims 33-36, 38, 40-48 are pending.

Election/Restriction

Applicant's election with traverse of Group I, in Paper No. 13 was acknowledged.

The examiner required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier.

Claim 33 is directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(B), claims 34-36, 38, 40-48, directed to the process of making or using an allowable product, previously withdrawn from consideration as a result of a restriction requirement, are hereby rejoined and fully examined for patentability under 37 CFR 1.104.

Art Unit: 1632

Because all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, the restriction requirement as set forth in the Office action mailed on October 1, 2002 is hereby withdrawn. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claims including all the limitations of an allowable product claim or rejoined process claim are presented in a continuation or divisional application, such claims may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Claims 33-36, 38, 40-48 are pending are currently under examination.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Claim and Specification Objections

Claim 33 objected to because neither the specification nor the claim have the appropriate deposit information is withdrawn.

Reasons for Allowance

The following is an examiner's statement of reasons for allowance:

The amendments to claim 33 and the specification have addressed the objections to the claim and specification indicated in the Quayle action. As noted previously, the evidence and declaration provided by Applicants have obviated the basis of the deposit requirement, and with the instant amendment claim 33 clearly reflects an enabled scope which is free of the art of record.

Method claims have been rejoined. Though the methodology has not been specifically discussed in previous office actions, review and examination of the specific method steps encompassed in the rejoined claims clearly indicates that they are drawn to routine methodology known and practiced in the art of transgenics. More specifically, the use of mouse embryonic stem cells to generate transgenic mice with alterations in their genome is routine. The novelty of the instant invention distinguishing it from the prior art is the use of a specific embryonic stem cell, dMsh2-9, where the gene encoding Msh has been altered, resulting in a cell with a reduced ability to recognize base pair mismatches, and thus having a greater capacity for the incorporation of less homologous sequences than cells that have an intact mismatch repair system.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Application/Control Number: 09/884,877 Page 5

Art Unit: 1632

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Woitach whose telephone number is (571) 272-0739.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached at (571) 272-0734.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group analyst Dianiece Jacobs whose telephone number is (571) 272-0532.

Joseph T. Woitach

JOSEPH WOTTACH, PH.D. PRIMARY EXAMINER

C) de Worter